PI3K/AKT/mTOR Pathway Emerges as Prime Target for Next-Gen Breast Cancer Therapies
A comprehensive review maps how a key cancer-driving pathway becomes hijacked in breast cancer and how new inhibitors and immunotherapy combinations could transform treatment.
Summary
The PI3K/AKT/mTOR signaling pathway is frequently dysregulated in breast cancer through mutations like PIK3CA and loss of the tumor suppressor PTEN, fueling unchecked tumor growth and treatment resistance. This 2025 review from City of Hope researchers synthesizes current knowledge on pathway-targeting inhibitors — including PI3K, AKT, and mTOR blockers — and evaluates combination strategies designed to overcome drug resistance. Emerging directions include next-generation inhibitors, biomarker-guided personalized treatment, and integration with immunotherapy to amplify anti-tumor immune responses. The authors argue these converging strategies hold significant promise for improving survival and quality of life in breast cancer patients worldwide.
Detailed Summary
Breast cancer remains one of the most prevalent and deadly cancers affecting women globally, demanding increasingly sophisticated treatment strategies. A central challenge is the frequent activation of the PI3K/AKT/mTOR signaling axis, a molecular pathway that governs cell growth, proliferation, and survival. When dysregulated, it drives aggressive tumor behavior and resistance to standard therapies.
This review, authored by researchers at City of Hope Comprehensive Cancer Center and published in Biochemical Pharmacology (2025), systematically examines how genetic alterations — particularly PIK3CA mutations and PTEN loss — lead to pathway overactivation in breast cancer. These are among the most common oncogenic events in hormone receptor-positive and HER2-positive subtypes, making this pathway a high-priority therapeutic target.
The review surveys the current landscape of approved and investigational inhibitors targeting PI3K, AKT, and mTOR individually and in combination. Notably, combination regimens appear more effective than monotherapy in circumventing the feedback loops and compensatory mechanisms that often blunt single-agent responses. Drugs like alpelisib (a PI3Kα inhibitor approved for PIK3CA-mutated breast cancer) exemplify early clinical translation of this approach.
Looking forward, the authors highlight next-generation inhibitors with improved selectivity and tolerability, as well as biomarker-driven patient stratification to identify who is most likely to benefit. Integrating PI3K/AKT/mTOR inhibitors with immunotherapy is identified as a particularly exciting frontier, with preclinical rationale suggesting synergistic enhancement of anti-tumor immunity.
As a review based solely on existing literature, it does not present new clinical trial data. Its value lies in synthesizing a rapidly evolving field, though readers should note that many highlighted strategies remain investigational and require validation in larger prospective trials.
Key Findings
- PIK3CA mutations and PTEN loss are primary drivers of PI3K/AKT/mTOR dysregulation in breast cancer.
- Combination inhibitor strategies show greater promise than monotherapy in overcoming treatment resistance.
- Biomarker-guided personalized therapy may improve patient selection and treatment precision.
- Pairing pathway inhibitors with immunotherapy could amplify anti-tumor immune responses.
- Next-generation PI3K/AKT/mTOR inhibitors with better selectivity are under active development.
Methodology
This is a narrative review article, not a primary clinical or preclinical study. Authors synthesized published literature on PI3K/AKT/mTOR pathway biology, genetic alterations, approved inhibitors, and emerging combination strategies in breast cancer. No original data, patient cohorts, or experimental models were generated.
Study Limitations
As a review, this paper does not generate new clinical evidence and may reflect publication bias toward positive findings. Many highlighted next-generation inhibitors and immunotherapy combinations remain investigational, lacking phase III validation. Access to only the abstract limits assessment of the review's comprehensiveness and methodology.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.